Cotreatment with Smac mimetics and demethylating agents induces both apoptotic and necroptotic cell death pathways in acute lymphoblastic leukemia cells

Cancer Letters

Volumn 375, Issue 1, 2016, Pages 127-132

  Gerges, Steve ^a   Rohde, Katharina ^a   Fulda, Simone ^a,b  

^a GOETHE UNIVERSITY   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Apoptosis; Demethylating agents; Leukemia; Necroptosis; Smac

Indexed keywords

ANTINEOPLASTIC AGENT; AZACITIDINE; BIRINAPANT; BV 6; CASPASE 3; CASPASE INHIBITOR; DABRAFENIB; DECITABINE; ETANERCEPT; INHIBITOR OF APOPTOSIS PROTEIN 1; INHIBITOR OF APOPTOSIS PROTEIN 2; N BENZYLOXYCARBONYL VALYLALANYLASPARTIC ACID FLUOROMETHYLKETONE; N [1 CYCLOHEXYL 2 [2 [4 (4 FLUOROBENZOYL) 2 THIAZOLYL] 1 PYRROLIDINYL] 2 OXOETHYL] 2 (METHYLAMINO)PROPANAMIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; BV6 PEPTIDE; CASPASE; DIABLO PROTEIN, HUMAN; MITOCHONDRIAL PROTEIN; MLKL PROTEIN, HUMAN; OLIGOPEPTIDE; PROTEIN KINASE; RECEPTOR INTERACTING PROTEIN SERINE THREONINE KINASE; RIPK3 PROTEIN, HUMAN; SIGNAL PEPTIDE;

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; GENE; GENE SILENCING; LEUKEMIA CELL; MLKL GENE; MOLECULAR MODEL; NECROPTOSIS; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN DEPLETION; RIP3 GENE; DRUG POTENTIATION; DRUG SCREENING; GENETICS; HUMAN; METABOLISM; MOLECULAR MIMICRY; NECROSIS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; AZACITIDINE; CASPASES; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; GENE KNOCKDOWN TECHNIQUES; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MITOCHONDRIAL PROTEINS; MOLECULAR MIMICRY; NECROSIS; OLIGOPEPTIDES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN KINASES; RECEPTOR-INTERACTING PROTEIN SERINE-THREONINE KINASES;

EID: 84961168079     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2016.02.040     Document Type: Article

References (32)

1. Pui C.H., Relling M.V., Downing J.R. Acute lymphoblastic leukemia. N. Engl. J. Med 2004, 350:1535-1548.
2. Stanulla M., Schrappe M. Treatment of childhood acute lymphoblastic leukemia. Semin. Hematol 2009, 46:52-63.
3. Fulda S. Tumor resistance to apoptosis. Int. J. Cancer 2009, 124:511-515.
4. Fulda S. Therapeutic opportunities for counteracting apoptosis resistance in childhood leukaemia. Br. J. Haematol 2009, 145:441-454.
5. Galluzzi L., Vitale I., Abrams J.M., Alnemri E.S., Baehrecke E.H., Blagosklonny M.V., et al. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ 2012, 19:107-120.
6. Fulda S., Debatin K.M. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006, 25:4798-4811.
7. Fulda S., Vucic D. Targeting IAP proteins for therapeutic intervention in cancer. Nat. Rev. Drug Discov 2012, 11:109-124.
8. Vanden Berghe T., Linkermann A., Jouan-Lanhouet S., Walczak H., Vandenabeele P. Regulated necrosis: the expanding network of non-apoptotic cell death pathways. Nat. Rev. Mol. Cell Biol 2014, 15:135-147.
9. Oberst A., Dillon C.P., Weinlich R., McCormick L.L., Fitzgerald P., Pop C., et al. Catalytic activity of the caspase-8-FLIP(L) complex inhibits RIPK3-dependent necrosis. Nature 2011, 471:363-367.
10. Fulda S. Inhibitor of Apoptosis (IAP) proteins in hematological malignancies: molecular mechanisms and therapeutic opportunities. Leukemia 2014, 28:1414-1422.
11. Hundsdoerfer P., Dietrich I., Schmelz K., Eckert C., Henze G. XIAP expression is post-transcriptionally upregulated in childhood ALL and is associated with glucocorticoid response in T-cell ALL. Pediatr. Blood Cancer 2010, 55:260-266.
12. Zawel L., Straub C., Firestone B., Sullivan J., Levine K., Porter D., et al. Therapeutic targeting of inhibitor of apoptosis proteins. In: proceedings of the 101st annual meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC; Philadelphia, PA: AACR. Cancer Res 2010, 70(78 Suppl.):138.
13. Jones P.A., Baylin S.B. The epigenomics of cancer. Cell 2007, 128:683-692.
14. Bhatla T., Wang J., Morrison D.J., Raetz E.A., Burke M.J., Brown P., et al. Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia. Blood 2012, 119:5201-5210.
15. Burke M.J., Lamba J.K., Pounds S., Cao X., Ghodke-Puranik Y., Lindgren B.R., et al. A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia. Am. J. Hematol 2014, 89:889-895.
16. Fulda S., Strauss G., Meyer E., Debatin K.M. Functional CD95 ligand and CD95 death-inducing signaling complex in activation-induced cell death and doxorubicin-induced apoptosis in leukemic T cells. Blood 2000, 95:301-308.
17. Fakler M., Loeder S., Vogler M., Schneider K., Jeremias I., Debatin K.M., et al. Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2-mediated resistance. Blood 2009, 113:1710-1722.
18. Schenk B., Fulda S. Reactive oxygen species regulate Smac mimetic/TNFalpha-induced necroptotic signaling and cell death. Oncogene 2015, 34:5796-5806.
19. Varfolomeev E., Blankenship J.W., Wayson S.M., Fedorova A.V., Kayagaki N., Garg P., et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell 2007, 131:669-681.
20. Bertrand M.J., Milutinovic S., Dickson K.M., Ho W.C., Boudreault A., Durkin J., et al. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol. Cell 2008, 30:689-700.
21. Vince J.E., Wong W.W., Khan N., Feltham R., Chau D., Ahmed A.U., et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 2007, 131:682-693.
22. Petersen S.L., Wang L., Yalcin-Chin A., Li L., Peyton M., Minna J., et al. Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell 2007, 12:445-456.
23. Sun L., Wang H., Wang Z., He S., Chen S., Liao D., et al. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell 2012, 148:213-227.
24. Fulda S. Exploiting inhibitor of apoptosis proteins as therapeutic targets in hematological malignancies. Leukemia 2012, 26:1155-1165.
25. Steinhart L., Belz K., Fulda S. Smac mimetic and demethylating agents synergistically trigger cell death in acute myeloid leukemia cells and overcome apoptosis resistance by inducing necroptosis. Cell Death Dis 2013, 4:e802.
26. Newton K., Dugger D.L., Wickliffe K.E., Kapoor N., de Almagro M.C., Vucic D., et al. Activity of protein kinase RIPK3 determines whether cells die by necroptosis or apoptosis. Science 2014, 343:1357-1360.
27. Loeder S., Fakler M., Schoeneberger H., Cristofanon S., Leibacher J., Vanlangenakker N., et al. RIP1 is required for IAP inhibitor-mediated sensitization of childhood acute leukemia cells to chemotherapy-induced apoptosis. Leukemia 2012, 26:1020-1029.
28. Belz K., Schoeneberger H., Wehner S., Weigert A., Bonig H., Klingebiel T., et al. Smac mimetic and glucocorticoids synergize to induce apoptosis in childhood ALL by promoting ripoptosome assembly. Blood 2014, 124:240-250.
29. Loeder S., Drensek A., Jeremias I., Debatin K.M., Fulda S. Small molecule XIAP inhibitors sensitize childhood acute leukemia cells for CD95-induced apoptosis. Int. J. Cancer 2010, 126:2216-2228.
30. Schoeneberger H., Belz K., Schenk B., Fulda S. Impairment of antioxidant defense via glutathione depletion sensitizes acute lymphoblastic leukemia cells for Smac mimetic-induced cell death. Oncogene 2015, 34:4032-4043.
31. Fulda S. Promises and challenges of Smac mimetics as cancer therapeutics. Clin. Cancer Res 2015, 21:5030-5036.
32. Laukens B., Jennewein C., Schenk B., Vanlangenakker N., Schier A., Cristofanon S., et al. Smac mimetic bypasses apoptosis resistance in FADD- or caspase-8-deficient cells by priming for tumor necrosis factor alpha-induced necroptosis. Neoplasia 2011, 13:971-979.